Non ci sono recensioni
Overview of Hematopoietic Cell Transplantation and Cellular Therapy
Pages 1-9
This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant and cellular therapy patients.
Spanning the timeline from the initial consultation throughout the transplant process, this handbook begins by providing a general overview of stem cell transplantation and goes on to outline disease-specific indications for stem cell transplantation. It then focuses on transplant complications and ongoing care, and finally explores cellular therapies for hematologic malignancies.
Comprehensive and easy-to-use, Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care, Third Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers as well as residents, fellows, and other trainees who care for patients who undergo transplant and immune effector cell therapy.
Overview of Hematopoietic Cell Transplantation and Cellular Therapy
Pages 1-9
The Business of Cellular Therapy and Hematopoietic Cell Transplantation
Pages 11-36
Hematopoietic Stem Cell Sources and Donor Selection
Pages 37-54
Pretransplant Assessment for Hematopoietic Cell Transplantation Recipients and Donors
Pages 55-72
Social Work: Evaluation and Social Supports
Pages 73-84
Conditioning Regimens
Pages 85-101
Pages 103-113
Physical and Occupational Therapy
Pages 115-125
Adolescent and Young Adult Concerns
Pages 127-139
Infection Prevention and Prophylaxis
Pages 141-151
Graft-Versus-Host Disease (GvHD) Prophylaxis
Pages 153-186
Transfusion Medicine
Pages 187-199
Anticoagulation and Antiplatelet Guidelines
Pages 201-223
Engraftment
Pages 225-230
Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant
Pages 231-250
Acute Lymphoblastic Leukemia
Pages 251-270
Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Pages 271-281
Multiple Myeloma
Pages 283-301
HCT for Germ Cell Tumors
Pages 303-310
Hematopoietic Cell Transplant for Myelofibrosis
Pages 311-327
Chronic Myeloid Leukemia
Pages 329-345
Chronic Lymphocytic Leukemia
Pages 347-353
Hematopoietic Cell Transplant for Severe Aplastic Anemia
Pages 355-368
Inherited Disorders
Pages 369-381
Hematopoietic Cell Transplant and Cellular Therapies for Sickle Cell Disease
Pages 383-399
Radiology Pearls for the Transplant Provider
Pages 401-422
Acute Graft-Versus-Host Disease (GvHD)
Pages 423-452
Chronic Graft-Versus-Host Disease
Pages 453-476
Immune Reconstitution
Pages 477-492
Infectious Complications
Pages 493-512
Oral Complications
Pages 513-530
Gastrointestinal Complications
Pages 531-541
Pulmonary Complications
Pages 543-555
Cardiovascular Complications
Pages 557-578
Kidney Disease in Hematopoietic Cell Transplantation
Pages 579-591
Neurological Complications
Pages 593-622
Endocrine Complications Following Hematopoietic Cell Transplantation
Pages 623-643
Thrombotic Microangiopathies
Pages 645-649
Women’s Health Care
Pages 651-662
Men’s Health for Hematopoietic Cell Transplant Patients
Pages 663-673
Psychiatric Complications
Pages 675-689
Graft Failure
Pages 691-700
Second Primary Malignancies
Pages 701-710
Relapse After Hematopoietic Cell Transplantation
Pages 711-721
Safe Pain Management with Opioids in Posttransplant Patients
Pages 723-745
Complementary Medicine: Acupuncture
Pages 747-757
Pages 759-767
Complementary Medicine: Cannabinoids and the Hematopoietic Cell Transplant (HCT) Recipient
Pages 769-779
Management of Neurocognitive Effects and Fatigue During and After Hematopoietic Cell Transplant
Pages 781-789
Palliative Care
Pages 791-805
Long-Term Follow-Up and Survivorship
Pages 807-828
CAR T Cells for Hematologic Malignancies
Pages 829-846
Natural Killer Cell Therapy in Allogeneic Hematopoietic Cell Transplantation
Pages 847-857
Mesenchymal Stromal Cells: Impact on Hematopoietic Cell Transplantation
Pages 859-870
T-Cell Therapeutics: Donor Lymphocyte Infusion, Cytotoxic T-Lymphocyte Infusion, and Other Non-CAR T-Cell Therapies
Pages 871-894
Dendritic Cell Vaccines
Pages 895-903
BiTEs, DARTs, and Peri-Transplant Minimal Residual Disease
Pages 905-913
CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity
Pages 915-928
Molecular Testing for Post-transplant Disease Surveillance
Pages 929-941
Management of Immune Compromised Transplant and Immune Effector Cell Treated Patients in the Setting of the COVID-19 Viral Pandemic: The OHSU Experience
Pages 943-949
Sei sicuro di voler eseguire questa azione?